Response to "Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes" (vol 60, 715, 2023)

被引：0

作者：

Cheema, Muhammad Rafay Shahzad ^{[1
]}

Kumar, Satesh ^{[2
]}

机构：

[1] Allama Iqbal Med Coll, Allama Shabbir Ahmad Usmani Rd, Lahore 54550, Punjab, Pakistan

[2] Shaheed Mohtarma Benazir Bhutto Med Coll, Karachi, Pakistan

来源：

ACTA DIABETOLOGICA | 2023年 / 60卷 / 5期

关键词：

D O I：

10.1007/s00592-023-02078-z

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：717 / 717

页数：1

共 50 条

[1] Response to "Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes"
Cheema, Muhammad Rafay Shahzad
Kumar, Satesh
[J]. ACTA DIABETOLOGICA, 2023, 60 (05) : 715 - 716
[2] Response to "Effects of Semaglutide on Cardiovascular Risk Factors and Eating Behaviors in Type 2 Diabetes"
Venjhraj, F. N. U.
Kumar, Mukesh
Ram, Meva
[J]. CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (10)
[3] Response to “Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes”
Muhammad Rafay Shahzad Cheema
Satesh Kumar
[J]. Acta Diabetologica, 2023, 60 : 715 - 716
[4] Correction to: Response to “Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes”
Muhammad Rafay Shahzad Cheema
Satesh Kumar
[J]. Acta Diabetologica, 2023, 60 : 717 - 717
[5] Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Ugo Di Folco
Noemi Vallecorsa
Maria Rosaria Nardone
Angelo Lauria Pantano
Claudio Tubili
[J]. Acta Diabetologica, 2022, 59 : 1287 - 1294
[6] Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Di Folco, Ugo
Vallecorsa, Noemi
Nardone, Maria Rosaria
Pantano, Angelo Lauria
Tubili, Claudio
[J]. ACTA DIABETOLOGICA, 2022, 59 (10) : 1287 - 1294
[7] Cardiovascular Risk of Semaglutide in Patients With Type 2 Diabetes
Marso
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (02) : 159 - 159
[8] A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
Yanai, Hidekatsu
Hakoshima, Mariko
Adachi, Hiroki
Katsuyama, Hisayuki
[J]. CARDIOLOGY RESEARCH, 2022, 13 (05) : 303 - 308
[9] Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
Doggrell, Sheila A.
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (05) : 489 - 492
[10] Type-2 Diabetes: Examination of cardiovascular Risk Profile of oral Semaglutide
Lichert, Frank
[J]. DIABETOLOGIE UND STOFFWECHSEL, 2019, 14 (06)

← 1 2 3 4 5 →